Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio Serv's gross profit for the
three
months ended in Apr. 2026 was $0.90 Mil. Pharma-Bio Serv's gross profit for the trailing twelve months (TTM) ended in Apr. 2026 was $2.95 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Pharma-Bio Serv's gross profit for the
three
months ended in Apr. 2026 was $0.90 Mil. Pharma-Bio Serv's Revenue for the
three
months ended in Apr. 2026 was $2.70 Mil. Therefore, Pharma-Bio Serv's Gross Margin % for the quarter that ended in Apr. 2026 was 33.37%.
Pharma-Bio Serv had a gross margin of 33.37% for the quarter that ended in Apr. 2026 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Pharma-Bio Serv was 32.35%. The lowest was 25.16%. And the median was 29.72%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pharma-Bio Serv had a gross margin of 33.37% for the quarter that ended in Apr. 2026 => Competition eroding margins
Pharma-Bio Serv Gross Profit Related Terms
Pharma-Bio Serv Gross Profit Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pharma-Bio Serv's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv Gross Profit vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Gross Profit distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.95 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pharma-Bio Serv (PBSV) has a Gross Profit of $2.95 Mil as of Apr. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Pharma-Bio Serv and its competitors.
Is Pharma-Bio Serv's Gross Profit too high?
Pharma-Bio Serv's current Gross Profit is $2.95 Mil. Overall, Pharma-Bio Serv has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Gross Profit compare to HCTI and BFRG?
Pharma-Bio Serv's Gross Profit of $2.95 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Healthcare Providers & Services company?
A good Gross Profit depends on the Healthcare Providers & Services industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Pharma-Bio Serv and its competitors. Pharma-Bio Serv's current Gross Profit is $2.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Possible Value Trap. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current Gross Profit is $2.95 Mil. Pharma-Bio Serv's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Gross Profit is $2.95 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
GuruFocus considers Pharma-Bio Serv to be Possible Value Trap.
Key valuation signals for PBSV:
Gross Profit: $2.95 Mil
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
45GF Score
Get the complete analysis for PBSV
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
